Madrigal Pharmaceuticals, Inc. Common Stock
MDGLMadrigal Pharmaceuticals, Inc. (MDGL) is a biopharmaceutical company focused on developing therapies for cardiovascular and metabolic diseases. It specializes in using innovative research to create targeted treatments, with a particular emphasis on conditions such as non-alcoholic steatohepatitis (NASH) and related liver diseases.
Company News
Ten large-cap stocks experienced significant declines during the week of January 5-9, 2026. Notable losers include Madrigal Pharmaceuticals (down 11.57%), First Solar (down 14.46% following a Jefferies downgrade), Astera Labs (down 12.18%), and Roblox (down 9.99%). Other major decliners include CoStar Group, American International Group, NRG Ener...
Madrigal Pharmaceuticals announced an exclusive global license agreement with Pfizer to develop ervogastat, a Phase 2 oral DGAT-2 inhibitor for MASH treatment. The deal includes a $50 million upfront payment to Pfizer, with ervogastat positioned as a complementary therapy to Madrigal's approved drug Rezdiffra for potential combination treatment. ...
The gene therapy market is projected to reach $36.55 billion by 2032, with the FDA approving three transformative cell therapies in December. Five biotech companies are advancing therapies across diabetes, sickle cell disease, cardiovascular disease, liver disease, and chronic granulomatous disease, with recent clinical data demonstrating signifi...
Novo Nordisk faces challenges in 2026 but shows potential for recovery through lower drug prices, new drug indications, and promising pipeline candidates like Amycretin, which could help stabilize revenue growth.
Madrigal Pharmaceuticals will participate in three upcoming healthcare investor conferences in November and December 2025, presenting live webcasts about their MASH treatment Rezdiffra.
